Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?
Authors:
- 30 January 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 34 (3) , 247-253
Abstract
Purpose of review: Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association. We present here a review of the associations and possible interconnections between these two common disease processes. Recent findings: Epidemiological studies are discordant regarding the impact of sex on this association and on the impact of MASLD on incident stone risk. The nature of kidney stones is rarely taken into account. A favorable milieu for uric acid kidney stone formation may be created by a lower urine pH resulting from defective ammonium production associated with insulin resistance, common in MASLD. Endogenous oxalate synthesis, a major risk factor for calcium oxalate kidney stones, may be increased in MASLD via decline in the activity of enzymes involved in the detoxification of glyoxylate, the immediate precursor of oxalate. Summary: The nature of kidney stones associated with MASLD and factors driving this association remain to be elucidated. Potential mechanisms identified underlying this include an increase in the risk factors for both uric acid and calcium oxalate kidney stones.Keywords
This publication has 55 references indexed in Scilit:
- Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art UpdateClinical Gastroenterology and Hepatology, 2024
- Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysisInternal and Emergency Medicine, 2024
- Diagnosis and management of primary hyperoxalurias: best practicesPediatric Nephrology, 2024
- A multisociety Delphi consensus statement on new fatty liver disease nomenclatureAnnals of Hepatology, 2023
- 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2022
- Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluriaCell Reports, 2021
- The influence of metabolic syndrome and its components on the development of nephrolithiasisAsian Journal of Urology, 2018
- Association between nephrolithiasis and fatty liver detected on non-enhanced CT for clinically suspected renal colicClinical Imaging, 2017
- The economic and clinical burden of nonalcoholic fatty liver disease in the United States and EuropeHepatology, 2016
- Ascorbic acid intake and oxalate synthesisUrolithiasis, 2016